141 related articles for article (PubMed ID: 10097953)
1. [Photodynamic therapy of cutaneous T-cell lymphoma at special sites].
Eich D; Eich HT; Otte HG; Ghilescu V; Stadler R
Hautarzt; 1999 Feb; 50(2):109-14. PubMed ID: 10097953
[TBL] [Abstract][Full Text] [Related]
2. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
3. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma.
Boehncke WH; König K; Rück A; Kaufmann R; Sterry W
Acta Derm Venereol; 1994 May; 74(3):201-5. PubMed ID: 7915462
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
6. [Cutaneous lymphomas].
Schad K; Baumann Conzett K; Cozzio A
Ther Umsch; 2010 Sep; 67(9):453-64. PubMed ID: 20806174
[TBL] [Abstract][Full Text] [Related]
7. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic alternatives in cutaneous T-cell lymphoma.
Holloway KB; Flowers FP; Ramos-Caro FA
J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
[TBL] [Abstract][Full Text] [Related]
9. Palliative local radiotherapy in the treatment of tumor-stage cutaneous T-cell lymphoma/mycosis fungoides.
Xu CC; Zhang T; Wang T; Liu J; Liu YH
Chin Med Sci J; 2014 Mar; 29(1):33-7. PubMed ID: 24698676
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma.
Zane C; Venturini M; Sala R; Calzavara-Pinton P
Photodermatol Photoimmunol Photomed; 2006 Oct; 22(5):254-8. PubMed ID: 16948827
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis.
Seyed Jafari SM; Cazzaniga S; Hunger RE
G Ital Dermatol Venereol; 2018 Dec; 153(6):827-832. PubMed ID: 29683282
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.
Orenstein A; Haik J; Tamir J; Winkler E; Trau H; Malik Z; Kostenich G
Dermatol Surg; 2000 Aug; 26(8):765-9; discussion 769-70. PubMed ID: 10940064
[TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
Coors EA; Schuler G; Von Den Driesch P
Eur J Dermatol; 2006; 16(4):391-3. PubMed ID: 16935796
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous lymphomas: single center experience of dermatology and hematology clinics.
Payzin B; Ogretmen Z; Cidem Yildirim A; Ozturk Durur S; Sentekin S
J BUON; 2014; 19(1):171-7. PubMed ID: 24659660
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
Ponte P; Serrão V; Apetato M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):716-21. PubMed ID: 19929938
[TBL] [Abstract][Full Text] [Related]
16. Photochemotherapy (PUVA) in the tumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group.
Molin L; Thomsen K; Volden G; Groth O
Acta Derm Venereol; 1981; 61(1):52-4. PubMed ID: 6164215
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature.
Quéreux G; Brocard A; Saint-Jean M; Peuvrel L; Knol AC; Allix R; Khammari A; Renaut JJ; Dréno B
J Am Acad Dermatol; 2013 Dec; 69(6):890-7. PubMed ID: 24041738
[TBL] [Abstract][Full Text] [Related]
18. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
